Department of Neurosurgery, Xinyi People's Hospital, Xinyi, Jiangsu 221400, P.R. China.
Department of Hematology, Xuzhou Children's Hospital, Xuzhou, Jiangsu 221006, P.R. China.
Mol Med Rep. 2018 Jan;17(1):1926-1932. doi: 10.3892/mmr.2017.8063. Epub 2017 Nov 15.
Malignant glioma is the most common cancer type of the nervous system and the mechanisms driving the occurrence and development remain unclear, preventing effective treatment of this disease. Therefore, novel and efficient therapies for glioma are required. MicroRNAs (miRNAs) are small non‑coding RNAs that act as oncogenes or tumor suppressors in human cancer. In the present study, it was confirmed that Yin Yang‑1 (YY1), a transcription factor that is part of the polycomb group protein (PcG) family, is a direct target of miR‑218 in human glioma cells. It was demonstrated that YY1 promoted glioma cell proliferation and miR‑218 could inhibit glioma cell proliferation by targeting YY1, and indirectly reduced the degradation of p53. Together the results indicate that miR‑218 functions as a tumor suppressor in human glioma and suggest that overexpression of miR‑218 may be a potential strategy for the treatment of human glioma in the future.
恶性神经胶质瘤是最常见的神经系统癌症类型,其发生和发展的机制仍不清楚,这阻碍了对这种疾病的有效治疗。因此,需要新的、有效的神经胶质瘤治疗方法。微小 RNA(miRNA)是一种小的非编码 RNA,在人类癌症中作为癌基因或肿瘤抑制因子发挥作用。在本研究中,证实了 Yin Yang-1(YY1),一种多梳组蛋白(PcG)家族的转录因子,是人类神经胶质瘤细胞中 miR-218 的直接靶标。研究表明,YY1 促进神经胶质瘤细胞增殖,miR-218 通过靶向 YY1 抑制神经胶质瘤细胞增殖,并间接降低 p53 的降解。研究结果表明,miR-218 在人类神经胶质瘤中作为一种肿瘤抑制因子发挥作用,提示 miR-218 的过表达可能是未来治疗人类神经胶质瘤的一种潜在策略。